| Unique ID issued by UMIN | UMIN000059912 |
|---|---|
| Receipt number | R000067761 |
| Scientific Title | Association between preoperative phase angle and 1-year mortality in patients undergoing transcatheter aortic valve implantation: a prospective observational study |
| Date of disclosure of the study information | 2025/11/28 |
| Last modified on | 2025/11/28 08:01:39 |
A study on body composition and prognosis in patients undergoing catheter treatment for aortic valve stenosis
A study on cardiac treatment and body composition
Association between preoperative phase angle and 1-year mortality in patients undergoing transcatheter aortic valve implantation: a prospective observational study
Phase angle and prognosis in TAVI patients
| Japan |
aortic valve stenosis
| Cardiology | Anesthesiology | Cardiovascular surgery |
| Adult |
Others
NO
The aim of this study is to clarify the association between preoperative phase angle (PhA) and 1-year all-cause mortality in patients undergoing TAVI, and to evaluate whether PhA remains an independent prognostic factor after adjustment for established risk factors.
Efficacy
The primary outcome is all-cause mortality within 1 year after TAVI. Mortality will be ascertained from hospital electronic medical records, outpatient clinic records, and, if necessary, telephone follow-up. The time point of evaluation is defined as one year after the date of the TAVI procedure.
Observational
| 18 | years-old | <= |
| Not applicable |
Male and Female
Patients scheduled to undergo transcatheter aortic valve implantation (TAVI) at our institution
Patients capable of providing written informed consent
Patients with pacemaker or implantable cardioverter-defibrillator (ICD), in whom bioelectrical impedance analysis (BIA) is contraindicated
Emergency cases
Patients on chronic dialysis
Valve-in-valve cases (redo transcatheter valve implantation within a previously implanted bioprosthetic valve)
Patients undergoing TAVI via non-transfemoral approaches
Patients converted to open surgical aortic valve replacement
150
| 1st name | Fujiwara |
| Middle name | |
| Last name | Atsushi |
Osaka Medical and Pharmaceutical University
Department of Anesthesiology
569-8686
2-7 Daigaku-machi, Takatsuki, Osaka, Japan
072-683-1221
atsushi.fujiwara@ompu.ac.jp
| 1st name | Mitsui |
| Middle name | |
| Last name | Hiroaki |
Osaka Medical and Pharmaceutical University
Department of Anesthesiology
569-8686
2-7 Daigaku-machi, Takatsuki, Osaka, Japan
072-683-1221
hiroaki.mitsui@ompu.ac.jp
Department of Anesthesiology, Osaka Medical and Pharmaceutical University
Department of Anesthesiology, Osaka Medical and Pharmaceutical University
Self funding
Department of Anesthesiology, Osaka Medical and Pharmaceutical University
2-7 Daigaku-machi, Takatsuki, Osaka, Japan
072-683-1221
hiroaki.mitsui@ompu.ac.jp
NO
| 2025 | Year | 11 | Month | 28 | Day |
Unpublished
Preinitiation
| 2025 | Year | 10 | Month | 23 | Day |
| 2025 | Year | 10 | Month | 23 | Day |
| 2025 | Year | 11 | Month | 12 | Day |
| 2029 | Year | 12 | Month | 31 | Day |
Preoperative phase angle (PhA) will be measured using bioelectrical impedance analysis (BIA). Clinical data including laboratory findings (albumin, hemoglobin, creatinine, BNP, LVEF, etc.) and comorbidities will be collected from electronic medical records. Patients will be followed for 1 year after TAVI by reviewing hospital records, outpatient records, or telephone contact to ascertain all-cause mortality (primary outcome).
| 2025 | Year | 11 | Month | 28 | Day |
| 2025 | Year | 11 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000067761